Summary of SenesTech (SNES) Conference Call - August 19, 2025 Company Overview - **Company**: SenesTech - **Ticker Symbol**: SNES - **Industry**: Biotech and Life Sciences, specifically pest control - **Core Product**: Rodent birth control solutions disrupting the rodenticide market, focusing on sustainable pest management [3][4] Key Points and Arguments Industry Context - **Rodent Problem**: Rodents cause over $27 billion in infrastructure damage annually in the U.S. and destroy nearly 20% of the world's food supply [4][5] - **Current Solutions**: Existing rodenticides are largely poisons that are ineffective and harmful, leading to resistance and bans in various jurisdictions [6][7] Product Differentiation - **Unique Approach**: SenesTech focuses on suppressing rodent reproduction rather than increasing mortality rates, with products that are humane and do not harm non-target species [11][12] - **Evolve Product**: Launched as a solid bait, it has an 18-month shelf life and is designed for both professional and DIY use, significantly expanding market reach [16][17] Market Position and Competitive Advantage - **Regulatory Head Start**: SenesTech has a FIFRA 25B minimum risk exemption and approvals in 48 states, giving it a significant advantage over competitors [18][19] - **Intellectual Property**: The company holds patents and trade secrets that protect its unique formulations and efficacy studies [20][21] Market Opportunities - **Market Size**: The U.S. rodenticide market is approximately $1 billion, with a global market of $4.5 billion [26][63] - **Target Verticals**: Key markets include consumers, cities and governments, pest management, agribusiness, facilities management, and food production [26][27] Sales and Distribution Strategy - **E-commerce Growth**: E-commerce accounts for over 60% of revenue, with a 78% increase year-over-year, driven by the popularity of Evolve [31][32] - **Municipal Deployments**: Significant traction in cities like Chicago and New York, with successful pilot programs leading to reorders and increased consumer adoption [36][38] Financial Performance - **Revenue Growth**: Total revenue is approximately $2 million annually, with Evolve sales increasing by 94%, making up 83% of second-quarter sales [51][52] - **Gross Margins**: Improved to 65.4% in Q2, driven by the profitability of the Evolve product [55] - **Cash Position**: The company ended the quarter with $6.1 million in cash, with a pro forma cash position of about $12 million, providing a runway into 2027 [60][61] Future Outlook - **Regulatory Tailwinds**: Increasing bans on traditional rodenticides and a push for humane alternatives create a favorable environment for SenesTech's products [63][64] - **Growth Strategy**: Focus on e-commerce, international markets, and government sales, with expectations for strong revenue growth and margin expansion [66][67] Additional Important Points - **International Expansion**: Successful pilot programs in markets like Hong Kong and the Netherlands, with potential for significant orders [43][44] - **Brick and Mortar Retail**: Recent agreements with distributors to expand into physical retail, with a nearly 500% increase in brick-and-mortar sales sequentially [46][47] This summary encapsulates the key insights from the SenesTech conference call, highlighting the company's innovative approach to pest control, market opportunities, and financial performance.

Core Insights - Gatorade recognizes exceptional high school athletes through its Player of the Year awards, celebrating their achievements in sports and community involvement [2][4][11] - The 2024-25 Gatorade Best Player of the Year winners are Cameron Boozer in boys basketball and Jane Hedengren in cross country and track & field, both of whom have demonstrated outstanding athletic performance and leadership [4][5][11] Gatorade Player of the Year Awards - The awards culminated in a week-long event in Los Angeles, featuring experiences such as meeting sports heroes, community service, and participation in educational events [2][3] - The event highlighted Gatorade's 60-year legacy in sports science, providing athletes with personalized insights on hydration and fueling needs [3] Athlete Achievements - Cameron Boozer, a senior power forward, led his team to a 30-3 record, averaging 22.1 points, 11.8 rebounds, and winning multiple accolades including the Naismith Trophy Award semifinalist [4][6] - Jane Hedengren, a senior distance runner, set multiple national high school records and won significant titles in cross country and track & field, including a course-record time at the Nike Cross Nationals [5][6] Gatorade Portfolio and PepsiCo - The Gatorade Portfolio, part of PepsiCo, includes brands like Propel and Muscle Milk, focusing on a comprehensive range of performance and wellness products for athletes [8] - PepsiCo reported nearly $92 billion in net revenue in 2024, driven by a diverse portfolio of beverages and convenient foods [9]

Summary of SenesTech (SNES) 2025 Conference Call Company Overview - **Company**: SenesTech, a biotech and life sciences company focused on rodent control through reproductive management rather than lethal methods [5][6] - **Ticker Symbol**: SNES, traded on NASDAQ [4] Core Product and Market Strategy - **Flagship Product**: Evolve, launched in 2024, is a soft bait designed for rodent fertility control, which has quickly become the top-selling product [12][14] - **Sales Growth**: Evolve sales grew by 40% year-over-year in Q1 2025 [15][37] - **Market Opportunity**: The U.S. rodenticide market is estimated at $1 billion annually, with a global market of $4.5 billion [34] Unique Selling Proposition - **Sustainable Approach**: Focus on controlling the birth rate of rodents rather than relying on poisons, which have social, political, and ecological drawbacks [6][8][30] - **Product Safety**: Evolve is designated as a minimum risk product by the EPA, using cottonseed oil as the active ingredient, making it safer for pets and wildlife [14][16] Distribution Channels - **Six Channel Strategy**: Includes e-commerce, agriculture distributors, pest management distributors, retail (e.g., Ace Hardware), international distributors, and direct sales to large customers [18][19] - **E-commerce Growth**: E-commerce sales increased by over 7%, with a run rate approaching $60,000 to $70,000 per month [20][21] Municipal and International Opportunities - **Municipal Deployments**: Significant projects in Chicago and New York City, with repeat orders indicating product effectiveness [23][24][25] - **International Expansion**: Exclusive distribution agreements signed in 12 countries, with expected approvals in Australia and New Zealand [27][28] Financial Performance - **Revenue Growth**: Record revenue of $1.9 million in 2024, up 56% from the previous year [39] - **Gross Margin Improvement**: Gross margins for Evolve reached 64%, compared to 32% in Q1 of the previous year [40] - **Cost Optimization**: Initiatives to reduce operating costs include pausing new product development and optimizing sales efforts [44] Future Outlook - **Path to Profitability**: Aiming for cash flow breakeven at approximately $1.5 million per quarter, with current revenues around $500,000 per quarter [45][46] - **Market Trends**: Increasing awareness of the need for humane rodent control solutions due to public health concerns and regulatory changes [52][53] Key Takeaways - **Transformative Opportunity**: SenesTech believes it has a paradigm-changing product that addresses long-standing rodent control issues in a sustainable manner [55][56] - **Execution Strategy**: Focus on expanding market presence, improving product offerings, and enhancing operational efficiencies to drive future growth [54][56]

Company Participation - SenesTech, Inc. will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 [1] - The webcast presentation is scheduled for 3:30 p.m. ET and will be accessible via the conference home page or directly through a provided link [2] - Management will engage in virtual one-on-one meetings throughout the event, with arrangements available through Lytham Partners [3] Company Overview - SenesTech is focused on improving global health by managing animal pest populations through fertility control solutions [4] - The company developed ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, along with Evolve and Evolve Mouse, which are EPA-designated minimum risk contraceptives for rodents [4] - SenesTech aims to integrate its products into pest management programs to enhance effectiveness and promote humane, safe, and sustainable pest control [4]

Core Insights - SenesTech, Inc. reported a 17% increase in revenues for Q1 2025, reaching $485,000 compared to $415,000 in Q1 2024, with Evolve product sales growing 40% year-over-year, now accounting for 79% of total revenue [8][3] - The company achieved a record gross profit margin of 64.5%, up from 32.5% in the same quarter last year [8] - The net loss for Q1 2025 was $1.7 million, slightly improved from a loss of $1.8 million in Q1 2024, while adjusted EBITDA loss improved to $1.5 million from $1.7 million [8] Operational and Strategic Highlights - The Evolve™ Rat and Evolve™ Mouse products are now the largest revenue drivers for SenesTech, reflecting a successful product expansion strategy [3] - E-commerce revenue more than doubled year-over-year, with a 107% increase attributed to improved platform functionality and digital marketing efforts [4] - The company has expanded Evolve deployments in major U.S. municipalities, with positive early adoption in Chicago and a pilot program in New York City [5] International Growth - SenesTech has signed distribution agreements in eleven countries and territories, with product shipments already initiated in The Netherlands, Hong Kong, the UAE, and the Maldives [6] - Regulatory approvals are pending in Australia and New Zealand, with additional launches planned for later in 2025 [6] Financial Performance - The company reported a gross profit of $313,000 for Q1 2025, compared to $135,000 in Q1 2024, indicating improved operational efficiency [17] - Total current assets increased to $3.164 million as of March 31, 2025, up from $2.813 million at the end of 2024 [16] - The company has lowered its breakeven revenue threshold from $12 million to approximately $7 million, indicating a path toward positive cash flow [6]

Financial Results Announcement - SenesTech, Inc. will report its first quarter 2025 financial results after market close on May 8, 2025 [1] - A conference call is scheduled for the same day at 5:00 p.m. Eastern time to review the results [1] Conference Call Details - Interested parties can access the conference call by dialing (844) 308-3351 or (412) 317-5407 [2] - A live webcast of the conference call will be available on the Company's website [2] Replay Information - A teleconference replay will be available for seven days after the call [3] - A webcast replay will be accessible for 90 days on the Company's website [3] Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control [4] - The company has developed ContraPest, the only U.S. EPA-registered contraceptive for rats, and other minimum risk contraceptives for rodents [4] - The mission is to provide proactive, safe, and sustainable pest management solutions [4]